Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model

二维码有效期 120s

作者 Chai Sanbao ^[1] Yu Shuqing ^[2] Liu Fengqi ^[2] Liu Zuoxiang ^[2] Yang Qingqing ^[2] Sun Feng ^[2] 学术成果认领

作者单位 Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing 102206, China ^[1] Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing 100191, China ^[2]

栏目名称 Correspondence

DOI 10.1097/CM9.0000000000002520

发布时间 2025-03-04

基金项目

National Natural Science Foundation of China

浏览5
被引0
下载0

中华医学杂志英文版

2023年136卷1期

102-104页

SCIMEDLINEISTICCSCDCABP

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model

Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model

中华医学杂志英文版

相似文献

中华医学杂志英文版

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model

Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model

中华医学杂志英文版

相似文献

中华医学杂志英文版

相关期刊

检索历史清除